C12P 21 - Preparation of peptides or proteins

Patents for C12P 21 - Preparation of peptides or proteins (112,499)
12/2002
12/03/2002	US6489126 To identify rheumatoid arthritis (ra), and also prepare reagents for the clinical diagnosis thereof
12/03/2002	US6489124 Neurotransmission by excitatory amino acids (eaas) such as glutamate is mediated via membrane-bound surface receptors. modulated by certain modulatory proteins. dna coding for a family of such modulatory proteins has now been isolated
12/03/2002	US6489122 Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide a containing a sequence of at least 5 consecutive amino acids in the polypeptide of seq id no: 1, dnas encoding the antigenic polypeptides, or dnas complementary thereto;
12/03/2002	US6489118 Nucleotide sequences coding preferential peptides; for use in diagnosing and treatment of allergies
12/03/2002	US6489106 Control of the expression of anchored genes using micron scale heaters
12/03/2002	US6489104 Screening for a dna encoding a protein that regulates the human p27.sup.kip1 promoter activity of a promoter dna, said promoter dna comprising at least a substantial portion of a fragment extending from nucleotide 2795 to nucleotide 3133 of
12/03/2002	US6488935 Dna coding for a peptide of a papilloma virus major capsid protein and a papilloma virus genome, respectively
12/03/2002	US6488930 Antibody or functional fragment thereof which binds to a mammalian (e.g., human) cc-chemokine receptor 4 (ccr4)
12/03/2002	CA2213198C Gene therapy by anti-tgf-b agents
12/03/2002	CA2126103C Transfection of lung via aerosolized transgene delivery
12/03/2002	CA2060544C Recombinant antibodies specific for a growth factor receptor
12/03/2002	CA2050910C Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
12/03/2002	CA2035474C Vaccine protecting against pig haemophilosis
12/03/2002	CA1341405C Methods of isolation and purification of g-csf
12/01/2002	CA2384109A1 Engineering nicking endonucleases from type iis restriction endonucleases
11/2002
11/30/2002	CA2388268A1 Methods of determining polypeptide structure and function
11/30/2002	CA2384352A1 Novel polynucleotides from streptomyces avermitilis
11/28/2002	WO2002095377A1 Method of screening germ for cell-free protein synthesis and method of producing germ extract for cell-free protein synthesis
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095051A2 Mage-a3 peptides presented by hla class ii molecules
11/28/2002	WO2002095039A1 Protease deficient caulobacter host cells
11/28/2002	WO2002095029A2 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	WO2002095028A1 Polynucleotide probe and primer for detecting beer-clouding lactic acid bacteria and method of detecting beer-clouding lactic acid bacteria
11/28/2002	WO2002095015A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	WO2002095012A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/28/2002	WO2002095003A2 Phytases, nucleic acids encoding them and methods for making and using them
11/28/2002	WO2002094990A2 Receptors and membrane-associated proteins
11/28/2002	WO2002094985A2 Beta-secretase substrates and uses thereof
11/28/2002	WO2002094881A2 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/28/2002	WO2002094880A1 Anti-trail-r antibodies
11/28/2002	WO2002094879A1 Antibodies specific for cd44v6
11/28/2002	WO2002094878A1 Hevein-binding monoclonal antibodies
11/28/2002	WO2002094876A2 Methods and compositions for treating respiratory mucin production associated disease conditions
11/28/2002	WO2002094872A1 Therapeutic uses of keratinocyte growth factor-2
11/28/2002	WO2002094871A1 Novel keratinocyte growth factor-2 analogue in hair follicle
11/28/2002	WO2002094864A2 Human cdnas and proteins and uses thereof
11/28/2002	WO2002094862A2 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	WO2002094861A2 Genes and proteins involved in the biosynthesis of enediyne ring structures
11/28/2002	WO2002094855A2 Peptide synthesis method
11/28/2002	WO2002094780A2 Kinases and phosphatases
11/28/2002	WO2002094314A1 Tsg101 as inhibitor of hiv production
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002057741A3 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
11/28/2002	WO2002056837A9 Inhibition of protein-phosphatases for the treatment of heart failure
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001098509A3 Grain processing method and transgenic plants useful therein
11/28/2002	WO2001098360A3 Gp354 nucleic acids and polypeptides
11/28/2002	WO2001096393A9 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020177565 Toso proteins and related molecules which have an inhibitory effect on TNF mediated apoptosis
11/28/2002	US20020177553 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177549 Which regulate cellular guidance and physiology, and related nucleic acids.
11/28/2002	US20020177210 Polypeptide for use as tools in food processing and genetic engineering
11/28/2002	US20020177209 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
11/28/2002	US20020177203 Alpha2 subunit of prolyl 4-hydroxylase
11/28/2002	US20020177200 Moraxella catarrahalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
11/28/2002	US20020177191 Compound for use inthe diagnosis and treatment of cancer, viral, asthmatic, autoimmune, organ transplant rejection and infections
11/28/2002	US20020177189 Novel fluorescent proteins
11/28/2002	US20020177188 IL-17 homologous polypeptides and therapeutic uses thereof
11/28/2002	US20020177187 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
11/28/2002	US20020177186 Controlling protein synthesis in situ; obtain amino acid sequence, associate acoustic frequency with amino acids, determine frequencies for amino acid sequence, determine tone quality, use tone to control biosynthesis of protein
11/28/2002	US20020177178 Compositions and methods for detection of ehrlichia canis and ehrlichia chaffeensis antibodies
11/28/2002	US20020177165 Secreted and transmembrane polypeptides and nucleic acids encoding
11/28/2002	US20020177164 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177160 Method of increasing complementarity in a heteroduplex
11/28/2002	US20020177158 Detection of preferential protein in sample; obtain pool of proteins, incubate with probe, detect signal from probe, recover proteins
11/28/2002	US20020177128 Variant of LAV viruses
11/28/2002	US20020177126 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
11/28/2002	US20020177124 Nucleotide sequences coding polypeptide for use in the detection, prevention and diagnosis viral diseases
11/28/2002	US20020176869 Hepatitus A virus vaccines
11/28/2002	US20020176864 Two-domain MHC polypeptides include MHC( major histocompatibility complex) class II-based molecules that covalently linked beta 1 and alpha 1 domains, and MHC class I-based molecules that covalently linked alpha-1 and alpha-2
11/28/2002	US20020176858 Monoclonal antibodies to TGF-BETA
11/28/2002	US20020176856 Administering an antibody to the mammal, that binds with a specified target epitope of an antigen, associated with a tumor or an infectious agent; having engineered glycosylation site in the constant region of the heavy chain antibodies
11/28/2002	CA2448253A1 Human cdnas and proteins and uses thereof
11/28/2002	CA2448174A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	CA2448142A1 Beta-secretase substrates and uses thereof
11/28/2002	CA2448014A1 Tsg101 as inhibitor of hiv production
11/28/2002	CA2447958A1 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	CA2447797A1 Protease deficient caulobacter host cells
11/28/2002	CA2447680A1 Hevein-binding monoclonal antibodies
11/28/2002	CA2447340A1 Kinases and phosphatases
11/28/2002	CA2447338A1 Receptors and membrane-associated proteins
11/28/2002	CA2447313A1 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/28/2002	CA2446398A1 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	CA2445972A1 Methods and compositions for treating respiratory mucin production associated disease conditions
11/28/2002	CA2443437A1 Antibodies specific for cd44v6
11/28/2002	CA2443342A1 Mage-a3 peptides presented by hla class ii molecules
11/28/2002	CA2441666A1 Phytases, nucleic acids encoding them and methods and using them
11/27/2002	EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002	EP1260521A2 Immunoglobulin variants for specific Fc epsilon receptors
11/27/2002	EP1260144A1 Process for producing soybean protein hydrolyzate
11/27/2002	EP1259813A2 Diagnosis and treatment of malignant neoplasms
11/27/2002	EP1259812A2 Breast, gastric and prostate cancer associated antigens and uses therefor
11/27/2002	EP1259650A2 Estrogen receptor alpha variants and methods of detection thereof
11/27/2002	EP1259642A1 Nucleic acids, proteins, and antibodies
11/27/2002	EP1259627A2 Heterologous expression of neisserial proteins
11/27/2002	EP1259616A2 Tnf-alpha variants for the treatment of tnf-alpha related disorders
11/27/2002	EP1259615A1 Human antibodies against eotaxin and their use
11/27/2002	EP1259614A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same

1 ... 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 ... 1125